P1135: subcutaneous epcoritamab in combination with ritxuimab + lenalidomide in relapsed or refractory follicular lymphoma: phase 1/2 trial update

D. Belada,S. Leppä,B. E. Wahlin,M. Nijland, J. H. Christensen,S. de Vos, H. Holte,K. M. Linton, A. Abbas, L. Wang, M. Dinh,B. Elliott,L. Falchi

HemaSphere（2022）

引用 0|浏览1

暂无评分

关键词

refractory follicular lymphoma,subcutaneous epcoritamab in combination,ritxuimab,lenalidomide

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要